Cargando…
Predicting Response to Vedolizumab in Inflammatory Bowel Disease
Vedolizumab is known to be safe, well-tolerated, and effective. However, as personalization becomes an increasingly important aspect of IBD care and in lieu of guidelines to inform clinicians on positioning of biologics, there is a need to reliably predict response to inform patient preferences and...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7145386/ https://www.ncbi.nlm.nih.gov/pubmed/32300596 http://dx.doi.org/10.3389/fmed.2020.00076 |